Comparison of patients who did and did not develop TLS on 1 or more occasions
| Characteristic . | Overall, N = 136∗ . | Occurrence of TLS . | P value‡ . | Adjusted P value§ . | |
|---|---|---|---|---|---|
| Yes, n = 7† . | No, n = 129† . | ||||
| TLS risk | .007 | ||||
| Low | 91 | 2 (2.2%) | 89 (98%) | ||
| Medium | 30 | 2 (6.7%) | 28 (93%) | ||
| High | 11 | 3 (27%) | 8 (73%) | ||
| Unknown | 4 | 0 | 4 | ||
| Age (y) | .12 | .11 | |||
| <70 | 67 | 1 (1.5%) | 66 (99%) | ||
| ≥70 | 69 | 6 (8.7%) | 63 (91%) | ||
| Race | .3 | .12 | |||
| White | 117 | 5 (4.3%) | 112 (96%) | ||
| Black or African American | 11 | 1 (9.1%) | 10 (91%) | ||
| Asian-Far East/Indian subcontinent | 3 | 0 (0%) | 3 (100%) | ||
| Other/unknown | 5 | 1 (20%) | 4 (80%) | ||
| ECOG performance status | .3 | .3 | |||
| 0 | 57 | 1 (1.8%) | 56 (98%) | ||
| 1 | 11 | 1 (9.1%) | 10 (91%) | ||
| 2 | 2 | 0 (0%) | 2 (100%) | ||
| Unknown | 66 | 5 | 61 | ||
| Venetoclax as frontline TX | > .9 | > .9 | |||
| No | 88 | 5 (5.7%) | 83 (94%) | ||
| Yes | 48 | 2 (4.2%) | 46 (96%) | ||
| Paired medication before venetoclax | .7 | .2 | |||
| No | 60 | 4 (6.7%) | 56 (93%) | ||
| Yes | 76 | 3 (3.9%) | 73 (96%) | ||
| CrCl (mL/min per 1.73 m2) at venetoclax initiation | .034 | .2 | |||
| ≥60 | 107 | 3 (2.8%) | 104 (97%) | ||
| <60 | 28 | 4 (14%) | 24 (86%) | ||
| Unknown | 1 | 0 | 1 | ||
| CrCl of <60 mL/min per 1.73 m2at least once | .072 | .6 | |||
| No | 101 | 3 (3.0%) | 98 (97%) | ||
| Yes | 35 | 4 (11%) | 31 (89%) | ||
| Site for venetoclax escalations | .061 | < .001 | |||
| All IP | 27 | 4 (15%) | 23 (85%) | ||
| Any IP | 35 | 1 (2.9%) | 34 (97%) | ||
| OP | 74 | 2 (2.7%) | 72 (97%) | ||
| Characteristic . | Overall, N = 136∗ . | Occurrence of TLS . | P value‡ . | Adjusted P value§ . | |
|---|---|---|---|---|---|
| Yes, n = 7† . | No, n = 129† . | ||||
| TLS risk | .007 | ||||
| Low | 91 | 2 (2.2%) | 89 (98%) | ||
| Medium | 30 | 2 (6.7%) | 28 (93%) | ||
| High | 11 | 3 (27%) | 8 (73%) | ||
| Unknown | 4 | 0 | 4 | ||
| Age (y) | .12 | .11 | |||
| <70 | 67 | 1 (1.5%) | 66 (99%) | ||
| ≥70 | 69 | 6 (8.7%) | 63 (91%) | ||
| Race | .3 | .12 | |||
| White | 117 | 5 (4.3%) | 112 (96%) | ||
| Black or African American | 11 | 1 (9.1%) | 10 (91%) | ||
| Asian-Far East/Indian subcontinent | 3 | 0 (0%) | 3 (100%) | ||
| Other/unknown | 5 | 1 (20%) | 4 (80%) | ||
| ECOG performance status | .3 | .3 | |||
| 0 | 57 | 1 (1.8%) | 56 (98%) | ||
| 1 | 11 | 1 (9.1%) | 10 (91%) | ||
| 2 | 2 | 0 (0%) | 2 (100%) | ||
| Unknown | 66 | 5 | 61 | ||
| Venetoclax as frontline TX | > .9 | > .9 | |||
| No | 88 | 5 (5.7%) | 83 (94%) | ||
| Yes | 48 | 2 (4.2%) | 46 (96%) | ||
| Paired medication before venetoclax | .7 | .2 | |||
| No | 60 | 4 (6.7%) | 56 (93%) | ||
| Yes | 76 | 3 (3.9%) | 73 (96%) | ||
| CrCl (mL/min per 1.73 m2) at venetoclax initiation | .034 | .2 | |||
| ≥60 | 107 | 3 (2.8%) | 104 (97%) | ||
| <60 | 28 | 4 (14%) | 24 (86%) | ||
| Unknown | 1 | 0 | 1 | ||
| CrCl of <60 mL/min per 1.73 m2at least once | .072 | .6 | |||
| No | 101 | 3 (3.0%) | 98 (97%) | ||
| Yes | 35 | 4 (11%) | 31 (89%) | ||
| Site for venetoclax escalations | .061 | < .001 | |||
| All IP | 27 | 4 (15%) | 23 (85%) | ||
| Any IP | 35 | 1 (2.9%) | 34 (97%) | ||
| OP | 74 | 2 (2.7%) | 72 (97%) | ||